EMA/210453/2018

European Medicines Agency decision

P/0144/2018

of 7 May 2018

on the acceptance of a modification of an agreed paediatric investigation plan for treprostinil (Remodulin and associated names), (EMEA-000207-PIP01-08-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0144/2018

of 7 May 2018

on the acceptance of a modification of an agreed paediatric investigation plan for treprostinil (Remodulin and associated names), (EMEA-000207-PIP01-08-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/121/2008 issued on 1 December 2008, the decision P/0074/2012 issued on 25 April 2012, the decision P/0291/2012 issued on 18 December 2012, the decision P/0308/2013 issued on 19 December 2013 and the decision P/0059/2015 issued on 1 April 2015,

Having regard to the application submitted by Ferrer Internacional, S.A. on 28 December 2017 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 March 2018, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for treprostinil (Remodulin and associated names), solution for infusion, subcutaneous use, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Ferrer Internacional, S.A., Avenida Diagonal 549, 5ª planta, 08029 - Barcelona, Spain.

EMA/PDCO/11835/2018
London, 23 March 2018

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000207-PIP01-08-M06

Scope of the application

Active substance(s):

Treprostinil

Invented name:

Remodulin and associated names

Condition(s):

Treatment of pulmonary arterial hypertension

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for infusion

Route(s) of administration:

Subcutaneous use

Intravenous use

Name/corporate name of the PIP applicant:

Ferrer Internacional, S.A.

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Ferrer Internacional, S.A. submitted to the European Medicines Agency on 28 December 2017 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/121/2008 issued on 1 December 2008, the decision P/0074/2012 issued on 25 April 2012, the decision P/0291/2012 issued on 18 December 2012, the decision P/0308/2013 issued on 19 December 2013 and the decision P/0059/2015 issued on 1 April 2015.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 23 January 2018.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of pulmonary arterial hypertension

The waiver applies to:

- children from one month to less than 12 years of age;
- solution for infusion, subcutaneous use, intravenous use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

2. Paediatric investigation plan

2.1. Condition:

Treatment of pulmonary arterial hypertension

2.1.1. Indication(s) targeted by the PIP

Treatment of pulmonary arterial hypertension

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to one month of age and from 12 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of an intravenous formulation
Non-clinical studies	0	Not applicable
Clinical studies	1	**Study 3** A comparative study of intravenously administered treprostinil in neonates with Persistent Pulmonary Hypertension of neonates (PPHN) treated in Paediatric Intensive Care Unit.

Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	1	**Study 2** Analyses of existing data to clarify the safety and efficacy of the parenteral formulation of treprostinil in children aged from 12 to less than 18 years, as systematic review.
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By March 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of pulmonary arterial hypertension

Authorised indications:

- Treatment of idiopathic or heritable pulmonary arterial hypertension (PAH) to improve exercise tolerance and symptoms of the disease in patients classified as NYHA (New York Heart Association) Class III.

Authorised pharmaceutical form(s):

Solution for infusion

Authorised route(s) of administration:

Subcutaneous use, intravenous use